Biography:
Dr. Yang finished his Ph.D. on Cell Biology and completed an extensive Post-Doctoral training at University of Calgary/Tom Baker Cancer Centre, Canada. He has ~30 years of translational and innovative drug development experience on cancer and inflammation from a range of leading pharmaceutical organizations, including Celgene, Amgen, Crown Biosciences, Kosan Biosciences and ImaginAb Inc. He has led or crucially contributed to drug discovery programs involving >20 novel targets in the areas of gene therapy, epigenetics, targeted therapy and I/O, which led to 15 INDs or Phase-III development. Dr. Yang’s expertise focuses on translational medicine and translational research in cancer and inflammation and he has published ~100 research papers or reports. Dr. Yang currently serves as an Executive Director on translational sciences, State Key Laboratory of Translational Medicine and Innovative Drug Development, Simcere Pharma Group. He held several management positions in the biotech industry including Executive Director, Cancer Biology, Global Scientific Research Innovation Organization of Crown Biosciences, Senior Director of Cancer Pharmacology, Crown Biosciences, and Head of Pharmacology at ImaginAb Inc.
Title : Guidance on MS animal model development: Experimental autoimmune encephalomyelitis models induced by different myelin oligodendrocyte glycoproteins exhibit differentiated pharmacological responses
Title : Considerations on MS animal modeling: Format of myelin immunogens used for experimental autoimmune encephalomyelitis model establishment may affect pharmacologic responses of anti-inflammatory drugs
Title : Generation and application of humanized mouse tumor models to expedite translational research for Immuno-Oncology